Circulating tumour cells by diagnostic leukapheresis mirror primary tumour heterogeneity in non-small cell lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON19904

Enrollment

Registered

2015-12-09

Start date

2016-01-01

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

circulating tumour cells (CTC) Non small cell lung carcinoma (NSCLC) Diagnostic leukapheresis (DLA) tumour heterogeneity circulerende tumor cellen (CTC) niet kleincellig long carcinoom (NSCLC) diagnostische leukopherese (DLA) tumor heterogeniteit

Interventions

All patients will undergo apharesis: A procedure regularly used by the hematological department in the treatment of leukemia patients to isolate mononuclear cells (MNCs) from blood. We use this method

Eligibility

Inclusion criteria

Inclusion criteria: Patients with a histologically proven pulmonary malignancy (all disease stages) Performance status 0-2 Patients using anticoagulants such as fraxodi or acenocoumarol are allowed, unless they have hemorrhagic events Signed informed consent

Exclusion criteria

Exclusion criteria: Patients with insufficient peripheral venes to undergo leukapheresis Haemorrhagic diathesis: recent CVA, major bleeding, ulcus duodeni Cardiac failure, LVEF<40% No growth factors are allowed

Design outcomes

Primary

Measure	Time frame
Number of CTC's and percentage of patients who had CTC's detected. And comparing the CTC detection percentage per disease stage (stage I-IV).	—

Secondary

Measure	Time frame
survival and mutations measured in the CTC's and the original tumour.	—

Contacts

Public ContactH.J.M. Groen

University Medical Center Groningen (UMCG), Department of Pulmonary Disease, Box 30001

h.j.m.groen@int.umcg.nl+31 (0)50 3616161

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)